Settlement agreement restricts generic market due to FDA approval of oral non-statin medicines, leading to ongoing patent litigation against Renata Limited.
1 report, 0 independent
Updated Jul 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Settlement agreement restricts generic market due to FDA approval of oral non-statin medicines, leading to ongoing patent litigation against Renata Limited.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Esperion Therapeutics
American pharmaceutical company
Nothing else this week.
- FDA
Related events
- Generic medicine services are seeking approval for launch from the FDA.
- FDA rated generic equivalent to brand Climara Pro.
- Litigation regarding FDA approval process.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
Coverage
Newest first; wire copies grouped- Unknown outlet